PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...
PALM BEACH GARDENS, Fla., Aug. 9, 2025 /PRNewswire/ -- For patients considering plastic surgery with underlying medical conditions, Dr. Thomas A. Pane, MD, offers...
ALAMEDA, Calif., July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord...
The opinion will now be referred to the European Commission for final regulatory decision on donanemab
INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and...
RIYADH, Saudi Arabia, July 09, 2025 (GLOBE NEWSWIRE) -- In a rare example of a lifelong bond between a patient and a healthcare institution, King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh has continued to support a patient since infancy, providing 22 years of continuous care for a rare genetic blood clotting disorder, ultimately culminating in a liver transplant—the first of its kind globally for this particular condition.
New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated...